Anti-inflammatory treatment test in people with schizophrenia
Treatments studied
Part of Mental health clinical trials.
This Phase 4 study tests how an anti-inflammatory approach affects people with schizophrenia or schizoaffective disorder who also have signs of body inflammation. It may help by targeting inflammation that could be linked to symptoms for some people.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be 18 to 55 years old and have a main diagnosis of schizophrenia or schizoaffective disorder
- Have higher inflammation on a blood test (CRP 2 mg/L or higher)
- Have reduced motivation or pleasure (a screening score above 17)
- Be able to give written consent and pass a urine drug screen at each study visit
- Not have certain medical infections or immune conditions (no autoimmune disease, no active hepatitis B/C, no HIV, and no active fungal or recent recurrent infections)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a new medication that targets immune system inflammation (IL-23) can help people with schizophrenia feel better. Researchers believe this immune approach might reduce symptoms when combined with regular antipsychotic treatment.
This trial tests whether combining an NMDA “signal-supporting” treatment with an anti-inflammatory medicine can reduce symptoms in people with schizophrenia who don’t respond well to usual antipsychotic drugs. If you’ve tried at least two antipsychotics and you’re still symptomatic, this study may be worth screening for.
This trial tests a combination of an NMDA-targeting medicine and an anti-inflammatory treatment for people with schizophrenia that has not responded well to several standard treatments, including clozapine. If you qualify, the goal is to see whether this combination improves symptoms more than usual care.
This Phase 2 trial tests whether a “synbiotic” supplement (a mix of probiotics and prebiotics) can reduce symptoms of schizophrenia or schizoaffective disorder. It may help by targeting gut-related immune and inflammation pathways that could affect brain symptoms.
This study looks at “biomarkers,” or blood measures, in people with schizophrenia who respond to clozapine. It may help researchers understand who benefits from clozapine and why, by linking test results to symptom changes.
This trial tests a JAK inhibitor (a type of anti-inflammatory drug) for depression that is linked to inflammation. If you have depression or bipolar depression and a high CRP level (a marker of inflammation), you may be eligible.
Hear when a new Schizophrenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.